A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

June 30, 2014

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Ramucirumab (IMC-1121B)

Administered intravenously

DRUG

Eribulin

Administered intravenously

Trial Locations (52)

10469

ImClone Investigational Site, The Bronx

11042

ImClone Investigational Site, Lake Success

13790

ImClone Investigational Site, Johnson City

15213

ImClone Investigational Site, Pittsburgh

20850

ImClone Investigational Site, Rockville

21044

ImClone Investigational Site, Columbia

22031

ImClone Investigational Site, Fairfax

23230

ImClone Investigational Site, Richmond

23502

ImClone Investigational Site, Norfolk

24153

ImClone Investigational Site, Salem

27215

ImClone Investigational Site, Burlington

27599

ImClone Investigational Site, Chapel Hill

29414

ImClone Investigational Site, Charleston

29605

ImClone Investigational Site, Greenville

30046

ImClone Investigational Site, Lawrenceville

31701

ImClone Investigational Site, Albany

32207

ImClone Investigational Site, Jacksonville

32806

ImClone Investigational Site, Orlando

33324

ImClone Investigational Site, Plantation

33612

ImClone Investigational Site, Tampa

33705

ImClone Investigational Site, St. Petersburg

33916

ImClone Investigational Site, Fort Myers

34952

ImClone Investigational Site, Port Saint Lucie

35211

ImClone Investigational Site, Birmingham

37203

ImClone Investigational Site, Nashville

37404

ImClone Investigational Site, Chattanooga

43623

ImClone Investigational Site, Toledo

45042

ImClone Investigational Site, Middletown

45429

ImClone Investigational Site, Dayton

48126

ImClone Investigational Site, Dearborn

55404

ImClone Investigational Site, Minneapolis

60068

ImClone Investigational Site, Park Ridge

63110

ImClone Investigational Site, St Louis

64507

ImClone Investigational Site, Saint Joseph

75075

ImClone Investigational Site, Plano

75246

ImClone Investigational Site, Dallas

75702

ImClone Investigational Site, Tyler

76014

ImClone Investigational Site, Arlington

76022

ImClone Investigational Site, Bedford

76104

ImClone Investigational Site, Fort Worth

77024

ImClone Investigational Site, Houston

77380

ImClone Investigational Site, The Woodlands

78217

ImClone Investigational Site, San Antonio

80220

ImClone Investigational Site, Denver

89074

ImClone Investigational Site, Henderson

92262

ImClone Investigational Site, Palm Springs

95020

ImClone Investigational Site, Gilroy

97213

ImClone Investigational Site, Portland

98684

ImClone Investigational Site, Vancouver

06489

ImClone Investigational Site, Southington

07960

ImClone Investigational Site, Morristown

05701

ImClone Investigational Site, Rutland

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01427933 - A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer | Biotech Hunter | Biotech Hunter